You are here

BCRF Grantee Since


Donor Recognition

The Housewares Charity Foundation Award

Area(s) of Focus

Stuart J. Schnitt, MD

Professor of Pathology, Harvard Medical School
Director, Division of Anatomic Pathology
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts

Current Research

Triple negative breast cancer (TNBC) comprises approximately 15% of all breast cancer and is defined by lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2). The clinical management of TNBC is challenging due its aggressive behavior and lack of targeted therapy. Some TNBCs express a receptor for the male hormones, androgens (AR+), which may be a target for treatment with anti-AR therapies. The majority of breast cancers that develop in women with inherited BRCA1 mutations are TNBC, but the frequency of AR positivity in BRCA1-associated TNBC has not been well studied. In their 2014-2015 BCRF project, Drs. Schnitt and Tung will compare the frequency of AR positivity in TNBC with and without an inherited BRCA1 mutation and evaluate whether AR is associated with any clinical factors or tumor pathologic factors. Determining the frequency of AR positivity in BRCA1+ TNBC could have significant clinical implications including the likelihood that AR inhibitors would be effective in this patient population.


Stuart J. Schnitt, MD, is the Director of the Division of Anatomic Pathology at Beth Israel Deaconess Medical Center, co-leader of the Dana Farber Harvard Cancer Center Breast Program, a Professor of Pathology at Harvard Medical School and an internationally recognized expert in breast pathology. He did his internship and residency in Anatomic and Clinical Pathology at Beth Israel Hospital in Boston followed by a fellowship in surgical pathology, also at Beth Israel Hospital. Dr. Schnitt has published over 300 original articles, review articles, editorials, commentaries, and book chapters, primarily in the area of breast disease. He has authored a popular breast pathology textbook entitled "Biopsy Interpretation of the Breast", now in its second edition; this book has also been published in Chinese. In addition, he is one of the editors of the 4th Edition of the "World Health Organization Classification of Tumours of the Breast", published in 2012. He has been cited in multiple editions of "The Best Doctors in America" and "America’s Top Doctors". Dr. Schnitt is a Past President of the United States and Canadian Academy of Pathology (2010-2011). His research interests have focused primarily on risk factors for local recurrence in patients with invasive breast cancer and ductal carcinoma in situ treated with breast conserving therapy, benign breast disease and breast cancer risk, and stromal-epithelial interactions in breast tumor progression.